Posters & Presentations

Scientific Posters and Presentations

Use the search tool to explore publications, posters and presentations and take a deep dive into our leadership in serious cardiovascular diseases.

In July 2026, Servier acquired Edgewise’s muscular dystrophy business, including sevasemten. To support patients, researchers, and healthcare professionals, sevasemten-related posters, presentations, and publications will remain accessible on this page for a limited time.

Cardiovascular

August 2026

ESC Congress 2026

CIRRUS-HCM: 12-Week Evaluation of the Safety and Efficacy of the Novel Cardiac Sarcomere Modulator EDG-7500in Nonobstructive and Obstructive Hypertrophic Cardiomyopathy

View Presentation

Muscular Dystrophy

July 2026

eBioMedicine

Effects of sevasemten (EDG-5506) on safety, biomarkers, and functional measures in adults with Becker muscular dystrophy: results of a phase 1b, open-label study

View Publication

Cardiovascular

May 2026

European Society of Cardiology – Heart Failure 2026

Acute administration of EDG-15400, a novel cardiac sarcomere modulator, improves left ventricular compliance and cardiac reserve in a genetic mini-pig model of HCM with relevance to HFpEF

View Poster

Cardiovascular

March 2026

American College of Cardiology Scientific Session & Expo

Reduced cardiac stress and inflammatory proteomic signatures in obstructive and nonobstructive HCM following EDG-7500 treatment in CIRRUS-HCM

View Poster

Muscular Dystrophy

March 2026

2026 MDA Clinical and Scientific Conference

Long-Term Stabilization of Function in Becker: Sevasemten Prevented Functional Decline Up to 3.5 Years with MESA Open-Label Extension

View Poster

Muscular Dystrophy

March 2026

Industry Forum at the 2026 MDA Clinical and Scientific Conference

Elevating Becker Outcomes: Unlocking New Insights, Mobilizing Communities, and Redefining Care

View Presentation

Muscular Dystrophy

March 2026

2026 MDA Clinical and Scientific Conference

Female carriers of BMD and DMD mutations show elevated muscle injury proteins, and muscle loss progression is predicted by plasma ART3 concentration

View Poster

Muscular Dystrophy

March 2026

2026 MDA Clinical and Scientific Conference

Effects of sevasemten on LVEF and NT-proBNP in adults with Becker muscular dystrophy in

View Poster

Muscular Dystrophy

March 2026

2026 MDA Clinical and Scientific Conference

Patient-Focused Drug Development: Understanding the Patient Experience and Meaningful Treatment Outcomes in Becker Muscular Dystrophy via Qualitative Interviews

View Poster

Posters & Presentations

CIRRUS-HCM: 12-Week Evaluation of the Safety and Efficacy of the Novel Cardiac Sarcomere Modulator EDG-7500in Nonobstructive and Obstructive Hypertrophic Cardiomyopathy

Effects of sevasemten (EDG-5506) on safety, biomarkers, and functional measures in adults with Becker muscular dystrophy: results of a phase 1b, open-label study

Acute administration of EDG-15400, a novel cardiac sarcomere modulator, improves left ventricular compliance and cardiac reserve in a genetic mini-pig model of HCM with relevance to HFpEF

Reduced cardiac stress and inflammatory proteomic signatures in obstructive and nonobstructive HCM following EDG-7500 treatment in CIRRUS-HCM

Long-Term Stabilization of Function in Becker: Sevasemten Prevented Functional Decline Up to 3.5 Years with MESA Open-Label Extension

Elevating Becker Outcomes: Unlocking New Insights, Mobilizing Communities, and Redefining Care

Female carriers of BMD and DMD mutations show elevated muscle injury proteins, and muscle loss progression is predicted by plasma ART3 concentration

Effects of sevasemten on LVEF and NT-proBNP in adults with Becker muscular dystrophy in

Patient-Focused Drug Development: Understanding the Patient Experience and Meaningful Treatment Outcomes in Becker Muscular Dystrophy via Qualitative Interviews

Footer

In the Clinic